From: Combination therapy with erythropoietin, magnesium sulfate and hypothermia for hypoxic-ischemic encephalopathy: an open-label pilot study to assess the safety and feasibility
N (%)
Severe neurodevelopmental disability
3 (38)
CP (GMFCS levelV)
2 (25)
Cognitive and language delay
1 (13)
Mild neurodevelopmental disability
0 (0)
Normal neurodevelopmental findings
5 (62)